About BrainStorm

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Learn More

Latest News

All News

NurOwn® Phase III Trial in ALS

BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.

For more information on enrollment, contact one of the participating clinical trial sites.

Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.

Learn More